Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Christer Fåhraeus, founder and CEO, has announced to the board of EQL Pharma AB that he wishes to continue his work for the company in a pure board capacity after the next Annual General Meeting of the company, scheduled for August 15, 2022. The board has therefore today agreed with Axel Schörling, deputy CEO, that he will take over the position as CEO for EQL Pharma AB starting after the next Annual General Meeting. Christer will remain CEO until this time, and then intends to be active as a board member and owner.
The background to the decision to name a new CEO earlier than usual is that it provides opportunities and time to prepare Axel Schörling to take over the role of CEO from Christer Fåhraeus for. Axel Schörling has been the company's Chief Operating Officer since 2018, and he was appointed Deputy CEO in 2020. Therefore, the board of EQL Pharma sees this succession as well prepared and planned.
Christer Fåhraeus will continue to be highly active in the company, not only during the remainder of his tenure as CEO, but also afterwards in his capacity as a member of the board and as a committed major shareholder in the company. Christer Fåhraeus has other corporate interests, not least through the investment company Fårö Capital AB and a startup Fund, and has expressed a desire to gradually reduce his daily and operational involvement in EQL Pharma AB, and therefore the succession to the CEO position has been planned for some time.
Axel Schörling has a double degree from Engineering Physics at Chalmers Institute of Technology and an MBA from Gothenburg School of Economics, and he has previously worked as a management consultant in the global consulting business BearingPoint. Axel was also previously responsible for Operations Controlling in Perstorp Group AB. As Chief Operating Officer at EQL Pharma, Axel has been instrumental in the company's rapid growth.
"It is of course a bit sad that current CEO and founder Christer Fåhraeus chooses to step down as CEO, but as Chairman of the Board, I am very happy that we can carry out this succession of the CEO in EQL in such a well-planned and controlled form," says Anders Månsson, Chairman of the Board of EQL Pharma AB. Headds, "I have gotten to know Axel since 2018 as an ambitious and driven leader in the operational activities, and the Board and I look forward to working with him when he takes over the full CEO responsibility for the company. "
"It is with a bit of emotion that I will leave the CEO chair at EQL, a company that has so many fantastic employees, but at the same time I feel extremely confident that Axel Schörling will do an outstanding job as the new CEO. I have worked with Axel on a daily basis for almost four years, and can say, with great confidence, that EQL will develop fantastically under his leadership ", says Christer Fåhraeus, CEO of EQL. "My plan is to stay a major shareholder of EQL for the foreseeable future, and to remain an active owner and board member for the long term."
"It is of course a great honor for me to be given the confidence to lead EQL, a company with fantastic staff and great potential that I strongly believe in. I am humble before the task and the responsibility it entails to manage the company's opportunities, and at the same time am full of energy to soon become the leader for taking the company to the next level. I would also like to take this opportunity to thank Christer for the fantastic work he has done since he founded the company in 2006, to bringing us to where we are today - an absolutely brilliant achievement, says Axel Schörling, CEO of EQL Pharma.
This disclosure contains information that EQL Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 10-11-2021 17:40 CET.